BTBP(SH:600161)2017-01-24 16:00Financial Performance - Total revenue for 2016 reached ¥208,410.13 million, an increase of 28.81% compared to ¥161,798.60 million in the previous year[2] - Operating profit surged to ¥35,211.00 million, reflecting a 93.71% increase from ¥18,177.63 million year-on-year[2] - Net profit attributable to shareholders was ¥25,337.66 million, a significant rise of 2,439.55% from ¥997.72 million in the prior year[2] - Basic earnings per share increased to ¥0.49, up 2,439.55% from ¥0.02 in the previous year[2] - Weighted average return on equity improved to 12.27%, an increase of 11.76 percentage points from 0.51%[2] Assets and Equity - Total assets at the end of the reporting period were ¥576,780.89 million, a 2.41% increase from ¥563,192.64 million at the beginning of the period[2] - Shareholders' equity attributable to the parent company rose to ¥218,688.01 million, up 12.63% from ¥194,158.20 million[2] Sales Performance - The sales revenue of blood products and net profit both experienced rapid growth during 2016[3] - Sales revenue of Class I vaccines increased year-on-year, with improvements in loss situations[3] - Sales revenue and profit from Class II vaccines significantly declined due to the ongoing impact of the "Shandong vaccine incident"[3]